Valeant Pharmaceuticals International Reports 2012 Fourth Quarter Financial Results

MONTREAL, Nov. 2, 2012 /PRNewswire/ --

•2012 Third Quarter Total Revenue $884 million?Organic growth (same store sales) was approximately 14% ?Pro forma organic growth was approximately 12%
•2012 Third Quarter GAAP EPS $0.02; Cash EPS $1.15
•2012 Third Quarter GAAP Cash Flow from Operations was $167 million; Adjusted Cash Flow from Operations was $241 million